Faster, cheaper & safer monoclonal antibody production

We have developed Swingo, a single-use bioreactor designed to enable biopharma companies to manufacture monoclonal antibodies faster, more cost-effectively, and with improved safety. Swingo streamlines the traditional six-step cell expansion process into a single step. The technology has been validated at industrial scale across multiple global biopharma companies, and we are preparing for commercial launch in mid-2026.